Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 74
Filtrar
1.
Dermatol Ther (Heidelb) ; 14(8): 2181-2193, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39009804

RESUMEN

INTRODUCTION: Lebrikizumab, a high-affinity IgG4 monoclonal antibody that selectively inhibits interleukin-13 with high binding affinity and slow dissociation rate, prevents the formation of the interleukin-4Rα/interleukin-13Rα1 heterodimer receptor signaling complex. Here we report the impact of lebrikizumab on responses to two non-live vaccines in adult patients with moderate-to-severe atopic dermatitis (AD). METHODS: ADopt-VA (NCT04626297) was a double-blind, placebo-controlled, parallel-group, 16-week, phase 3 randomized study to assess the impact of lebrikizumab treatment on non-live vaccine immune responses, and efficacy and safety of lebrikizumab compared with placebo. Eligible patients included adults from 18 to 55 years of age with moderate-to-severe chronic AD who were randomly assigned 1:1 to lebrikizumab 250 mg every 2 weeks or placebo and stratified according to disease severity. The primary endpoints were the development of a booster response to tetanus toxoid and a positive antibody response to meningococcal conjugate vaccine (MCV), 4 weeks after administration of the corresponding vaccine. RESULTS: At week 16, 73.6% of patients in the lebrikizumab group (n = 78/106) achieved Tdap booster response compared with 73.4% of patients in the placebo group (n = 58/79). MCV vaccine response was observed in 86.9% of patients in the lebrikizumab group (n = 86/99) and 75.0% of patients in the placebo group (n = 60/80). At week 16, IGA 0,1 with ≥ 2-point improvement from baseline was achieved by 40.6% (n = 51/125) of patients treated with lebrikizumab and 18.9% (n = 23/122) of patients who received placebo (p < 0.001). There was a higher proportion of patients achieving EASI 75 at week 16 in the lebrikizumab-treated patients (58.0%, n = 72/125) compared with placebo (32.7%, n = 40/122, p < 0.001). CONCLUSIONS: Treatment with lebrikizumab did not impact response to non-live vaccines Tdap and MCV in this study. Lebrikizumab treatment had a significant degree of efficacy compared to placebo across multiple endpoints. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04626297.

2.
Melanoma Manag ; 11(1): MMT68, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38812731

RESUMEN

Aim: Cutaneous melanocytic neoplasms with diagnostic and/or clinical ambiguity pose patient management challenges. Methods: Six randomized case scenarios with diagnostic/clinical uncertainty were described with/without a benign or malignant diagnostic gene expression profile (GEP) result. Results: Clinical impact was assessed by reporting the mean increase/decrease of management changes normalized to baseline (n = 32 dermatologists). Benign GEP results prompted clinicians to decrease surgical margins (84.2%). Malignant GEP results escalated surgical excision recommendations (100%). A majority (72.2%) reduced and nearly all (98.9%) increased follow-up frequency for benign or malignant GEP results, respectively. There was an overall increase in management plan confidence with GEP results. Conclusion: Diagnostic GEP tests help guide clinical decision-making in a variety of diagnostically ambiguous or clinicopathologically discordant scenarios.


Dermatologists' use of diagnostic gene expression profiles for personalized patient care. When your doctor takes a piece of a mole, that mole is looked at under the microscope by a pathologist. The pathologist is responsible for figuring out if the mole is dangerous or not. Dangerous moles are removed with surgery to make sure all the dangerous tissue is gone. Moles without a health threat are left alone. Sometimes figuring out how dangerous a mole is is difficult. The pathologist may not provide the doctor with enough information for them to know how to treat your mole. There is a test that can provide information on whether your mole is unsafe. This test is called diagnostic gene expression profiling or GEP. In this study, GEP is used to help doctors figure out how to treat a mole and how often the patient should be seen in the office for skin checks. With GEP, important changes in patient treatment were identified. These include the need for an additional surgery, how much healthy tissue should be removed during surgery and how often the patient should be seen in the office. For suspicious moles where the pathology report is unclear, GEP can provide information that leads to more appropriate and personalized patient care.


Ancillary diagnostic gene expression profile testing for ambiguous cutaneous melanocytic lesions helps optimize dermatologist recommendations for excision margin and follow-up.

3.
Micromachines (Basel) ; 13(11)2022 Nov 19.
Artículo en Inglés | MEDLINE | ID: mdl-36422456

RESUMEN

Miniaturized mechanical testing based on small sample testing technology is a powerful technique to characterize the mechanical properties of different materials, and it is being used in different application fields. However, the small size of the specimens poses several challenges because the results are highly sensitive to measurement accuracy and the corresponding mechanical properties can change substantially due to the so-called specimen size effect. In this work, a novel testing device based on miniaturized specimens is presented. The equipment is designed to test materials in tensile and compressive loadings, but it is also capable of performing reverse-loading tests. Buckling of the specimen is an inherent phenomenon in compression loadings, especially for thin materials. Therefore, specimen geometry is properly studied and optimized to mitigate this effect. To evaluate the deformation of the specimen, the digital image correlation (DIC) technique is used to capture the full-field strain in the central gauge section of the sample. A sensitivity analysis of the DIC setting parameters was performed for this application. To evaluate the performance of the developed system, experimental results of monotonic tests and tests with reverse loadings (tension-compression) are presented, considering two high-strength steels (DP500 and DP780).

4.
Int J Mater Form ; 15(5): 61, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35855077

RESUMEN

This article details the ESAFORM Benchmark 2021. The deep drawing cup of a 1 mm thick, AA 6016-T4 sheet with a strong cube texture was simulated by 11 teams relying on phenomenological or crystal plasticity approaches, using commercial or self-developed Finite Element (FE) codes, with solid, continuum or classical shell elements and different contact models. The material characterization (tensile tests, biaxial tensile tests, monotonic and reverse shear tests, EBSD measurements) and the cup forming steps were performed with care (redundancy of measurements). The Benchmark organizers identified some constitutive laws but each team could perform its own identification. The methodology to reach material data is systematically described as well as the final data set. The ability of the constitutive law and of the FE model to predict Lankford and yield stress in different directions is verified. Then, the simulation results such as the earing (number and average height and amplitude), the punch force evolution and thickness in the cup wall are evaluated and analysed. The CPU time, the manpower for each step as well as the required tests versus the final prediction accuracy of more than 20 FE simulations are commented. The article aims to guide students and engineers in their choice of a constitutive law (yield locus, hardening law or plasticity approach) and data set used in the identification, without neglecting the other FE features, such as software, explicit or implicit strategy, element type and contact model.

5.
Curr Med Res Opin ; 38(8): 1267-1274, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35081854

RESUMEN

OBJECTIVE: National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma (CM) recommend physicians consider increased surveillance for patients who typically have lower melanoma survival rates (stages IIB-IV as determined by the American Joint Committee on Cancer (AJCC), 8th edition). However, up to 15% of patients identified as having a low recurrence risk (stages I-IIA) experience disease recurrence, and some patients identified as having a high recurrence risk will not experience any recurrence. The 31-gene expression profile test (31-GEP) stratifies patient recurrence risk into low (Class 1) and high (Class 2) and has demonstrated risk-appropriate impact on disease management and clinical decisions. METHODS: Five-year plans for lab work, frequency of clinical visits, and imaging pre- and post-31-GEP test results were assessed for a cohort of 509 stage I-III patients following an interim subset analysis of 247 patients. RESULTS: After receiving 31-GEP results, 50.6% of patients had a change in management plans in at least one of the following categories-clinical visits, lab work, or surveillance imaging. The changes aligned with the risk predicted by the 31-GEP for 76.1% of patients with a Class 1 result and 78.7% of patients with a Class 2 result. A Class 1 31-GEP result was associated with changes toward low-intensity management recommendations, while a Class 2 result was associated with changes toward high-intensity management recommendations. CONCLUSION: The 31-GEP can stratify patient recurrence risk in patients with CM, and clinicians understand and apply the prognostic ability of the 31-GEP test to alter patient management in risk-appropriate directions.


When caught early, cancer of the skin can usually be removed, and patients have excellent chances of survival. However, some patients will have their cancer come back or spread to a new location in their body.The 31-gene expression profile (GEP) test measures the expression levels of 31 genes from an individual patient's tumor. A proprietary formula uses this information to identify the risk of recurrence or spread as low risk (Class 1) or high risk (Class 2). Cancers with low-risk 31-GEP scores have a lower chance of cancer recurrence or spread than patients with a high-risk score.In this study, we wanted to determine if doctors treated patients with low-risk scores differently from patients with high-risk scores. We found that doctors changed approximately half of patient treatment plans (doctor visits, lab work, or imaging to see if the cancer has come back) after learning the 31-GEP test results. Doctors usually planned less frequent follow-up visits for Class 1 results and more frequent follow up for Class 2 results.This study found doctors understand and make changes to their treatment plans based on the patient's 31-GEP test result.


Asunto(s)
Melanoma , Neoplasias Cutáneas , Perfilación de la Expresión Génica/métodos , Humanos , Melanoma/genética , Melanoma/terapia , Estadificación de Neoplasias , Pronóstico , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/terapia , Transcriptoma , Melanoma Cutáneo Maligno
6.
PLoS One ; 16(10): e0258831, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34665826

RESUMEN

Cancer causes mitochondrial alterations in skeletal muscle, which may progress to muscle wasting and, ultimately, to cancer cachexia. Understanding how exercise adaptations are altered by cancer and cancer treatment is important for the effective design of exercise interventions aimed at improving cancer outcomes. We conducted an exploratory study to investigate how tumor burden and cancer immunotherapy treatment (anti-PD-1) modify the skeletal muscle mitochondrial response to exercise training in mice with transplantable tumors (B16-F10 melanoma and EO771 breast cancer). Mice remained sedentary or were provided with running wheels for ~19 days immediately following tumor implant while receiving no treatment (Untreated), isotype control antibody (IgG2a) or anti-PD-1. Exercise and anti-PD-1 did not alter the growth rate of either tumor type, either alone or in combination therapy. Untreated mice with B16-F10 tumors showed increases in most measured markers of skeletal muscle mitochondrial content following exercise training, as did anti-PD-1-treated mice, suggesting increased mitochondrial content following exercise training in these groups. However, mice with B16-F10 tumors receiving the isotype control antibody did not exhibit increased skeletal muscle mitochondrial content following exercise. In untreated mice with EO771 tumors, only citrate synthase activity and complex IV activity were increased following exercise. In contrast, IgG2a and anti-PD-1-treated groups both showed robust increases in most measured markers following exercise. These results indicate that in mice with B16-F10 tumors, IgG2a administration prevents exercise adaptation of skeletal muscle mitochondria, but adaptation remains intact in mice receiving anti-PD-1. In mice with EO771 tumors, both IgG2a and anti-PD-1-treated mice show robust skeletal muscle mitochondrial exercise responses, while untreated mice do not. Taken together, we postulate that immune modulation may enhance skeletal muscle mitochondrial response to exercise in tumor-bearing mice, and suggest this as an exciting new avenue for future research in exercise oncology.


Asunto(s)
Inhibidores de Puntos de Control Inmunológico/administración & dosificación , Inmunoglobulina G/administración & dosificación , Neoplasias Mamarias Experimentales/terapia , Melanoma Experimental/terapia , Mitocondrias Musculares/metabolismo , Músculo Esquelético/metabolismo , Condicionamiento Físico Animal/métodos , Animales , Línea Celular Tumoral , Citrato (si)-Sintasa/metabolismo , Complejo IV de Transporte de Electrones/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Inhibidores de Puntos de Control Inmunológico/farmacología , Inmunoglobulina G/farmacología , Inmunoterapia , Neoplasias Mamarias Experimentales/inmunología , Neoplasias Mamarias Experimentales/metabolismo , Melanoma Experimental/inmunología , Melanoma Experimental/metabolismo , Ratones , Músculo Esquelético/efectos de los fármacos , Distribución Aleatoria , Resultado del Tratamiento
7.
Immunol Lett ; 239: 60-71, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34480981

RESUMEN

Immune checkpoint inhibition is highly effective in treating a subset of patients with certain cancers, such as malignant melanoma. However, a large proportion of patients will experience treatment resistance, and other tumour types, such as breast cancer, have thus far proven largely refractory to immune checkpoint inhibitors as single agents. Exercise has been associated with improved cancer patient survival, has known immune-modulatory effects, may improve anti-tumour immunity and may normalise tumour blood vessels. Therefore, we hypothesised that post-implant exercise would boost the effect of concurrent immunotherapy by enhancing anti-tumour immune responses and improving tumour blood flow. To investigate this, mice with EO771 breast tumours or B16-F10 melanomas received anti-PD-1, an isotype control antibody or no treatment. Mice were randomised to exercise (voluntary wheel running) or no exercise at tumour implant. Exercise reduced the number of CD8+T cells in EO771 (p = 0.0011) but not B16-F10 tumours (p = 0.312), and reduced the percentage of CD8+T cells within the total T cell population in both tumour types (B16-F10: p = 0.0389; EO771: p = 0.0015). In contrast, the combination of exercise and anti-PD-1 increased the percentage of CD8+T cells in EO771 (p = 0.0339) but not B16-F10 tumours. Taken together, our results show that exercise and anti-PD-1 induce changes in the tumour immune microenvironment which are dependant on tumour type.


Asunto(s)
Neoplasias de la Mama/terapia , Terapia por Ejercicio , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Melanoma Experimental/terapia , Neoplasias Cutáneas/terapia , Animales , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/patología , Terapia Combinada/métodos , Resistencia a Antineoplásicos/inmunología , Femenino , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología , Melanoma Experimental/inmunología , Melanoma Experimental/patología , Ratones , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Linfocitos T Citotóxicos/inmunología , Microambiente Tumoral/efectos de los fármacos , Microambiente Tumoral/inmunología
8.
Antioxidants (Basel) ; 10(3)2021 Mar 11.
Artículo en Inglés | MEDLINE | ID: mdl-33799728

RESUMEN

Tumour-associated macrophages (TAMs) are ubiquitously present in tumours and commonly associated with poor prognosis. In immune cells, ascorbate affects epigenetic regulation, differentiation and phenotype via its co-factor activity for the 2-oxoglutarate dependent dioxygenase enzymes. Here, we determined the effect of ascorbate on TAM development in response to tumour microenvironmental cues. Naïve murine bone marrow monocytes were cultured with Lewis Lung Carcinoma conditioned media (LLCM) or macrophage colony-stimulating factor (MCSF) to encourage the development into tumour-associated macrophages. Cells were stimulated with hypoxia (1% O2), with or without ascorbate (500 µM) supplementation. Cells and media were harvested for gene, cell surface marker and protein analyses. LLCM supported bone marrow monocyte growth with >90% of cells staining CD11b+F4/80+, indicative of monocytes/macrophages. LLCM-grown cells showed increased expression of M2-like and TAM genes compared to MCSF-grown cells, which further increased with hypoxia. In LLCM-grown cells, ascorbate supplementation was associated with increased F4/80 cell surface expression, and altered gene expression and protein secretion. Our study shows that ascorbate modifies monocyte phenotype when grown under tumour microenvironmental conditions, but this was not clearly associated with either a pro- or anti-tumour phenotype, and reflects a complex and nuanced response of macrophages to ascorbate. Overall, ascorbate supplementation clearly has molecular consequences for TAMs, but functional and clinical consequences remain unknown.

10.
J Synchrotron Radiat ; 27(Pt 6): 1703-1706, 2020 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-33147197

RESUMEN

The design and construction of an instrument for full-field imaging of the X-ray fluorescence emitted by a fully illuminated sample are presented. The aim is to produce an X-ray microscope with a few micrometers spatial resolution, which does not need to scan the sample. Since the fluorescence from a spatially inhomogeneous sample may contain many fluorescence lines, the optic which will provide the magnification of the emissions must be achromatic, i.e. its optical properties must be energy-independent. The only optics which fulfill this requirement in the X-ray regime are mirrors and pinholes. The throughput of a simple pinhole is very low, so the concept of coded apertures is an attractive extension which improves the throughput by having many pinholes, and retains the achromatic property. Modified uniformly redundant arrays (MURAs) with 10 µm openings and 50% open area have been fabricated using gold in a lithographic technique, fabricated on a 1 µm-thick silicon nitride membrane. The gold is 25 µm thick, offering good contrast up to 20 keV. The silicon nitride is transparent down into the soft X-ray region. MURAs with various orders, from 19 up to 73, as well as their respective negative (a mask where open and closed positions are inversed compared with the original mask), have been made. Having both signs of mask will reduce near-field artifacts and make it possible to correct for any lack of contrast.

11.
PLoS One ; 15(3): e0229290, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32187204

RESUMEN

Preclinical studies have shown a larger inhibition of tumour growth when exercise begins prior to tumour implant (preventative setting) than when training begins after tumour implant (therapeutic setting). However, post-implantation exercise may alter the tumour microenvironment to make it more vulnerable to treatment by increasing tumour perfusion while reducing hypoxia. This has been shown most convincingly in breast and prostate cancer models to date and it is unclear whether other tumour types respond in a similar way. We aimed to determine whether tumour perfusion and hypoxia are altered with exercise in a melanoma model, and compared this with a breast cancer model. We hypothesised that post-implantation exercise would reduce tumour hypoxia and increase perfusion in these two models. Female, 6-10 week old C57BL/6 mice were inoculated with EO771 breast or B16-F10 melanoma tumour cells before randomisation to either exercise or non-exercising control. Exercising mice received a running wheel with a revolution counter. Mice were euthanised when tumours reached maximum ethical size and the tumours assessed for perfusion, hypoxia, blood vessel density and proliferation. We saw an increase in heart to body weight ratio in exercising compared with non-exercising mice (p = 0.0008), indicating that physiological changes occurred with this form of physical activity. However, exercise did not affect vascularity, perfusion, hypoxia or tumour growth rate in either tumour type. In addition, EO771 tumours had a more aggressive phenotype than B16-F10 tumours, as inferred from a higher rate of proliferation (p<0.0001), a higher level of tumour hypoxia (p = 0.0063) and a higher number of CD31+ vessels (p = 0.0005). Our results show that although a physiological training effect was seen with exercise, it did not affect tumour hypoxia, perfusion or growth rate. We suggest that exercise monotherapy is minimally effective and that future preclinical work should focus on the combination of exercise with standard cancer therapies.


Asunto(s)
Neoplasias de la Mama/patología , Melanoma Experimental/patología , Condicionamiento Físico Animal/métodos , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Animales , Neoplasias de la Mama/irrigación sanguínea , Neoplasias de la Mama/metabolismo , Línea Celular Tumoral , Femenino , Humanos , Melanoma Experimental/irrigación sanguínea , Melanoma Experimental/metabolismo , Ratones , Ratones Endogámicos C57BL , Trasplante de Neoplasias , Distribución Aleatoria , Carrera , Hipoxia Tumoral , Microambiente Tumoral
12.
Cutis ; 99(2): E22-E24, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28319635

RESUMEN

Lupus erythematosus tumidus (LET) is a unique subset of chronic cutaneous lupus erythematosus (CCLE) that generally presents as urticarialike papules and plaques with induration and erythema on the face, trunk, and upper extremities. Lesions rarely present on the scalp or below the waist. We report a unique case of LET on the scalp of a woman that presented clinically as alopecia areata. Resistance to the standard treatment for alopecia areata prompted a biopsy that proved the diagnosis.


Asunto(s)
Alopecia Areata/diagnóstico , Lupus Eritematoso Discoide/diagnóstico , Cuero Cabelludo/patología , Alopecia Areata/patología , Biopsia , Femenino , Humanos , Lupus Eritematoso Discoide/patología , Persona de Mediana Edad
13.
MULTIMED ; 19(5)2015. tab
Artículo en Español | CUMED | ID: cum-68835

RESUMEN

La fibromialgia es una enfermedad frecuente en la práctica médica y la etiología de la misma permanece aún oscura, relacionándose con factores emocionales. Se realizó un estudio transversal con pacientes fibromiálgicos del Centro Médico Ambulatorio del Hospital Carlos M. de Céspedes, con el objetivo de identificar los factores psicosociales que se presentan en ellos. Se estudiaron variables demográficas; presencia de depresión, desesperanza e ideación suicida, percepción del dolor y eventos vitales. Se utilizó el análisis estadístico mediante porcentajes y como estadística inferencial el test Chi Cuadrado. Predominaron las mujeres, con edades entre 35 y 44 años, que tenían un empleo y pareja estable. El 77,3 por ciento tenían depresión y 34,8 por ciento de los deprimidos manifestaron ideación suicida. Más de la mitad de la muestra tenía desesperanza. Las personas con fibromialgia y depresión presentan con más frecuencia dolor exagerado a la presión y mayor número de eventos vitales que los no deprimidos. Se concluye que la depresión tiene una elevada prevalencia en los pacientes fibromiálgicos, al parecer relacionado con mecanismos etiopatogénicos comunes, que hacen pensar que esta entidad es una forma enmascarada de depresión o que la depresión puede ser una reacción adaptativa a la fibromialgia(AU)


Fibromyalgia is a common disease in the medical practice and its etiology remains dark, relating to the emotional factors. It was performed a cross-sectional study in patients with fibromyalgia in the Medical Ambulatory Center at Carlos M. de Céspedes Hospital, with the aim to identify thepsychosocial factors that occur in them. There were studied some demographic variables, like the presence of depression, hope lessness and suicidal ideation, pain perception and vital events. The statistical analysis was used by percentages, and as inferential statistical, it was applied the Chi Square test. There was a prevalence of women about 35 and 44 years old, which had a job and a stable partner. 77.3 percent presented depression and 34.8 percent of the depressed patients expressed suicidal ideation. More than a half of the sample presented hopelessness. People with fibromyalgia and depression more often presented exaggerated pressure pain and a greatest amount of vital events than the non depressed patients. It is concluded that depression is highly prevalent in patients with fibromyalgia, apparently related to common ethiopathogenic mechanisms, which suggested that this entity is a disguised form of depression or that depression may be an adaptive response to fibromyalgia(EU)


Asunto(s)
Humanos , Fibromialgia/epidemiología , Fibromialgia/psicología , Fibromialgia/terapia , Depresión/psicología , Estudios Transversales
14.
Clin Nucl Med ; 40(4): 322-4, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25243946

RESUMEN

Squamoid eccrine ductal carcinoma is an extremely uncommon type of eccrine carcinoma (EC). An important distinguishing feature of EC is potential for metastasis. Eccrine carcinoma has been reported to metastasize in up to 50% of cases. Despite tumor aggressivity, no recommendations for staging exist. We present the case of a 91-year-old woman with a lesion involving the left index finger confirmed to be squamoid eccrine ductal carcinoma by dermatopathologic evaluation. 18F-FDG PET/CT images revealed widespread multifocal FDG-avid metastatic disease. Although rare, staging of EC with 18F-FDG PET/CT imaging of the entire body is indicated.


Asunto(s)
Carcinoma Ductal/diagnóstico por imagen , Imagen Multimodal , Tomografía de Emisión de Positrones , Neoplasias de las Glándulas Sudoríparas/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Anciano de 80 o más Años , Femenino , Fluorodesoxiglucosa F18 , Humanos , Radiofármacos
16.
Am J Physiol Gastrointest Liver Physiol ; 305(10): G712-21, 2013 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-24008358

RESUMEN

Hydrogen sulfide (H2S) has been reported to be involved in the signaling of the inflammatory response; however, there are differing views as to whether it is pro- or anti-inflammatory. In this study, we sought to determine whether endogenously synthesized H2S via cystathionine-γ-lyase (CSE) plays a pro- or anti-inflammatory role in caerulein-induced pancreatitis. To investigate this, we used mice genetically deficient in CSE to elucidate the function of CSE in caerulein-induced acute pancreatitis. We compared the inflammatory response and tissue damage of wild-type (WT) and CSE knockout (KO) mice following 10 hourly administrations of 50 µg/kg caerulein or saline control. From this, we found that the CSE KO mice showed significantly less local pancreatic damage as well as acute pancreatitis-associated lung injury compared with the WT mice. There were also lower levels of pancreatic eicosanoid and cytokines, as well as reduced acinar cell NF-κB activation in the CSE KO mice compared with WT mice. Additionally, in WT mice, there was a greater level of pancreatic CSE expression and sulfide-synthesizing activity in caerulein-induced pancreatitis compared with the saline control. When comparing the two saline-treated control groups, we noted that the CSE KO mice showed significantly less pancreatic H2S-synthesizing activity relative to the WT mice. These results indicate that endogenous H2S generated by CSE plays a key proinflammatory role via NF-κB activation in caerulein-induced pancreatitis, and its genetic deletion affords significant protection against acute pancreatitis and associated lung injury.


Asunto(s)
Ceruletida/toxicidad , Cistationina gamma-Liasa/metabolismo , Pancreatitis/inducido químicamente , Animales , Cistationina gamma-Liasa/genética , Regulación de la Expresión Génica/fisiología , Sulfuro de Hidrógeno/metabolismo , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , FN-kappa B/genética , FN-kappa B/metabolismo , Pancreatitis/genética , Pancreatitis/metabolismo , Proteína Quinasa C/genética , Proteína Quinasa C/metabolismo
17.
Dermatol Surg ; 39(9): 1334-9, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23789591

RESUMEN

BACKGROUND: Repair of below-the-knee lower extremity defects after Mohs micrographic surgery (MMS) that are not amenable to primary closure can be challenging given the high propensity for complications. No criterion standard exists for management of these wounds, but secondary-intention healing, partial- and full-thickness skin grafts (FTSGs), and various flaps are possible options to manage these wounds. Few data exist on the efficacy of FTSG repairs for lower extremity wounds. OBJECTIVES: Assess the efficacy and complications rates of FTSG repairs for lower extremity wounds after MMS. METHODS: This was a retrospective review of 80 FTSG repairs performed after MMS. Data were derived from 45 cases at Beth Israel Deaconess Medical Center and 35 cases at University of California, San Diego (UCSD) Medical Center. RESULTS: Seventy-two of 80 cases (90%) had full graft survival, six (7.5%) had partial failure, and two (2.5%) had complete failure. In the cases where grafts had failed, wounds healed by secondary intention without further complications. Other complications included infections in nine (11%) cases and hematoma formation in two (2.5%). CONCLUSION: FTSG is a consistent and safe reconstructive option for the management of lower extremity wounds after MMS.


Asunto(s)
Cirugía de Mohs/efectos adversos , Trasplante de Piel , Infección de la Herida Quirúrgica/etiología , Técnicas de Cierre de Heridas , Anciano , Anciano de 80 o más Años , Hematoma/etiología , Humanos , Pierna , Persona de Mediana Edad , Estudios Retrospectivos , Trasplante de Piel/efectos adversos , Insuficiencia del Tratamiento , Técnicas de Cierre de Heridas/efectos adversos
19.
PLoS One ; 7(3): e32574, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22396778

RESUMEN

Hydrogen sulfide (H(2)S), a novel gaseous messenger, is synthesized endogenously from L-cysteine by two pyridoxal-5'-phosphate-dependent enzymes, cystathionine ß-synthase (CBS) and cystathionine γ-lyase (CSE). S-propargyl-cysteine (SPRC) is a slow H(2)S releasing drug that provides cysteine, a substrate of CSE. The present study was aimed to investigate the effects of SPRC in an in vivo model of acute pancreatitis (AP) in mice. AP was induced in mice by hourly caerulein injections (50 µg/kg) for 10 hours. Mice were treated with SPRC (10 mg/kg) or vehicle (distilled water). SPRC was administered either 12 h before or 3 h before the induction of pancreatitis. Mice were sacrificed 1 h after the last caerulein injection. Blood, pancreas and lung tissues were collected and processed to measure the plasma amylase, plasma H(2)S, myeloperoxidase (MPO) activities and cytokine levels in pancreas and lung. The results revealed that significant reduction of inflammation, both in pancreas and lung was associated with SPRC given 3 h prior to the induction of AP. Furthermore, the beneficial effects of SPRC were associated with reduction of pancreatic and pulmonary pro-inflammatory cytokines and increase of anti-inflammatory cytokine. SPRC administered 12 h before AP induction did not cause significant improvement in pancreatic and lung inflammation. Plasma H(2)S concentration showed significant difference in H(2)S levels between control, vehicle and SPRC (administered 3 h before AP) treatment groups. In conclusion, these data provide evidence for protective effects of SPRC in AP possibly by virtue of its slow release of endogenous H(2)S.


Asunto(s)
Ceruletida/metabolismo , Cisteína/análogos & derivados , Pancreatitis/metabolismo , Enfermedad Aguda , Amilasas/metabolismo , Animales , Antiinflamatorios no Esteroideos/farmacología , Cisteína/farmacología , Citocinas , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática/métodos , Gases , Sulfuro de Hidrógeno/farmacología , Inflamación , Pulmón/metabolismo , Pulmón/patología , Masculino , Ratones , Páncreas/metabolismo , Páncreas/patología , Pancreatitis/inducido químicamente , Peroxidasa/metabolismo , Factores de Tiempo
20.
J Am Acad Dermatol ; 66(5): 780-4, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-21875759

RESUMEN

BACKGROUND: We observed that basal cell carcinoma (BCC) on the ear demonstrates a more aggressive phenotype compared with other body sites. OBJECTIVE: We sought to determine if it is statistically significant that BCC on the ear is more aggressive. METHODS: We queried our 2009 database for all BCCs biopsied from the ear. Multiple data points, including tumor subtype and risk level, were analyzed for 100 BCCs on the ear and 100 BCCs on the cheek. RESULTS: BCC on the ear was diagnosed 471 times. Of the first 100 occurrences of BCC on the ear, 57% were high risk compared with 38% on the cheek (odds ratio 2.16, 95% confidence interval 1.23-3.81, P = .01). Men were more likely to have BCC on the ear: 79% male on the ear and 53% male on the cheek (P < .001). However, BCC on the ear in women is also more likely to be aggressive (57%, 12 of 21). LIMITATIONS: The data were retrieved from a single year at our institution, and there could potentially be regional bias given that the population of data is from a single institution. Many of the specimens we evaluate are reviewed in consultation and may thus represent a selection bias. CONCLUSION: BCC on the ear presents as an aggressive phenotype in the majority of cases for both men and women, and it occurs much more frequently in men. Knowledge of this information can help guide physicians and ensure that these tumors are adequately biopsied and treated.


Asunto(s)
Carcinoma Basocelular/epidemiología , Carcinoma Basocelular/patología , Oído Externo/patología , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/patología , Distribución por Edad , Anciano , Biopsia con Aguja , California/epidemiología , Carcinoma Basocelular/genética , Estudios de Cohortes , Intervalos de Confianza , Bases de Datos Factuales , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Invasividad Neoplásica/patología , Oportunidad Relativa , Fenotipo , Pronóstico , Medición de Riesgo , Distribución por Sexo , Neoplasias Cutáneas/genética , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA